Cargando…

Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review

OBJECTIVE: Evaluate evidence of the efficacy, safety, acceptability and cost-effectiveness of outpatient parenteral antimicrobial therapy (OPAT) models. DESIGN: A systematic review. DATA SOURCES: MEDLINE, EMBASE, CINAHL, Cochrane Library, National Health Service (NHS) Economic Evaluation Database (E...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitchell, E D, Czoski Murray, C, Meads, D, Minton, J, Wright, J, Twiddy, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775457/
https://www.ncbi.nlm.nih.gov/pubmed/28428184
http://dx.doi.org/10.1136/bmjopen-2016-013560
_version_ 1783293912425693184
author Mitchell, E D
Czoski Murray, C
Meads, D
Minton, J
Wright, J
Twiddy, M
author_facet Mitchell, E D
Czoski Murray, C
Meads, D
Minton, J
Wright, J
Twiddy, M
author_sort Mitchell, E D
collection PubMed
description OBJECTIVE: Evaluate evidence of the efficacy, safety, acceptability and cost-effectiveness of outpatient parenteral antimicrobial therapy (OPAT) models. DESIGN: A systematic review. DATA SOURCES: MEDLINE, EMBASE, CINAHL, Cochrane Library, National Health Service (NHS) Economic Evaluation Database (EED), Research Papers in Economics (RePEc), Tufts Cost-Effectiveness Analysis (CEA) Registry, Health Business Elite, Health Information Management Consortium (HMIC), Web of Science Proceedings, International Pharmaceutical Abstracts, British Society for Antimicrobial Chemotherapy website. Searches were undertaken from 1993 to 2015. STUDY SELECTION: All studies, except case reports, considering adult patients or practitioners involved in the delivery of OPAT were included. Studies combining outcomes for adults and children or non-intravenous (IV) and IV antibiotic groups were excluded, as were those focused on process of delivery or clinical effectiveness of 1 antibiotic over another. Titles/abstracts were screened by 1 reviewer (20% verified). 2 authors independently screened studies for inclusion. RESULTS: 128 studies involving >60 000 OPAT episodes were included. 22 studies (17%) did not indicate the OPAT model used; only 29 involved a comparator (23%). There was little difference in duration of OPAT treatment compared with inpatient therapy, and overall OPAT appeared to produce superior cure/improvement rates. However, when models were considered individually, outpatient delivery appeared to be less effective, and self-administration and specialist nurse delivery more effective. Drug side effects, deaths and hospital readmissions were similar to those for inpatient treatment, but there were more line-related complications. Patient satisfaction was high, with advantages seen in being able to resume daily activities and having greater freedom and control. However, most professionals perceived challenges in providing OPAT. CONCLUSIONS: There were no systematic differences related to the impact of OPAT on treatment duration or adverse events. However, evidence of its clinical benefit compared with traditional inpatient treatment is lacking, primarily due to the dearth of good quality comparative studies. There was high patient satisfaction with OPAT use but the few studies considering practitioner acceptability highlighted organisational and logistic barriers to its delivery.
format Online
Article
Text
id pubmed-5775457
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-57754572018-02-02 Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review Mitchell, E D Czoski Murray, C Meads, D Minton, J Wright, J Twiddy, M BMJ Open Health Services Research OBJECTIVE: Evaluate evidence of the efficacy, safety, acceptability and cost-effectiveness of outpatient parenteral antimicrobial therapy (OPAT) models. DESIGN: A systematic review. DATA SOURCES: MEDLINE, EMBASE, CINAHL, Cochrane Library, National Health Service (NHS) Economic Evaluation Database (EED), Research Papers in Economics (RePEc), Tufts Cost-Effectiveness Analysis (CEA) Registry, Health Business Elite, Health Information Management Consortium (HMIC), Web of Science Proceedings, International Pharmaceutical Abstracts, British Society for Antimicrobial Chemotherapy website. Searches were undertaken from 1993 to 2015. STUDY SELECTION: All studies, except case reports, considering adult patients or practitioners involved in the delivery of OPAT were included. Studies combining outcomes for adults and children or non-intravenous (IV) and IV antibiotic groups were excluded, as were those focused on process of delivery or clinical effectiveness of 1 antibiotic over another. Titles/abstracts were screened by 1 reviewer (20% verified). 2 authors independently screened studies for inclusion. RESULTS: 128 studies involving >60 000 OPAT episodes were included. 22 studies (17%) did not indicate the OPAT model used; only 29 involved a comparator (23%). There was little difference in duration of OPAT treatment compared with inpatient therapy, and overall OPAT appeared to produce superior cure/improvement rates. However, when models were considered individually, outpatient delivery appeared to be less effective, and self-administration and specialist nurse delivery more effective. Drug side effects, deaths and hospital readmissions were similar to those for inpatient treatment, but there were more line-related complications. Patient satisfaction was high, with advantages seen in being able to resume daily activities and having greater freedom and control. However, most professionals perceived challenges in providing OPAT. CONCLUSIONS: There were no systematic differences related to the impact of OPAT on treatment duration or adverse events. However, evidence of its clinical benefit compared with traditional inpatient treatment is lacking, primarily due to the dearth of good quality comparative studies. There was high patient satisfaction with OPAT use but the few studies considering practitioner acceptability highlighted organisational and logistic barriers to its delivery. BMJ Publishing Group 2017-04-20 /pmc/articles/PMC5775457/ /pubmed/28428184 http://dx.doi.org/10.1136/bmjopen-2016-013560 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
spellingShingle Health Services Research
Mitchell, E D
Czoski Murray, C
Meads, D
Minton, J
Wright, J
Twiddy, M
Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review
title Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review
title_full Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review
title_fullStr Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review
title_full_unstemmed Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review
title_short Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review
title_sort clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: civas systematic review
topic Health Services Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775457/
https://www.ncbi.nlm.nih.gov/pubmed/28428184
http://dx.doi.org/10.1136/bmjopen-2016-013560
work_keys_str_mv AT mitchelled clinicalandcosteffectivenesssafetyandacceptabilityofcommunityintravenousantibioticservicemodelscivassystematicreview
AT czoskimurrayc clinicalandcosteffectivenesssafetyandacceptabilityofcommunityintravenousantibioticservicemodelscivassystematicreview
AT meadsd clinicalandcosteffectivenesssafetyandacceptabilityofcommunityintravenousantibioticservicemodelscivassystematicreview
AT mintonj clinicalandcosteffectivenesssafetyandacceptabilityofcommunityintravenousantibioticservicemodelscivassystematicreview
AT wrightj clinicalandcosteffectivenesssafetyandacceptabilityofcommunityintravenousantibioticservicemodelscivassystematicreview
AT twiddym clinicalandcosteffectivenesssafetyandacceptabilityofcommunityintravenousantibioticservicemodelscivassystematicreview